SeaStar Medical Holding Corporation
As of Oct 22, 2026, SeaStar Medical Holding is in Stage 4, the downtrend phase, now in its first week (since Oct 20, 2026). It closed at $2.85, 54.8% below its 52-week high and below its 200-day average, which is rising.
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ICU early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ICU among Biotechnology377th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …377 | ICU | Stage 4 · wk 1 | 21 | −19.3% |
SeaStar Medical Holding: quick answers
What stage is SeaStar Medical Holding in?
As of Oct 22, 2026, SeaStar Medical Holding (ICU) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 20, 2026 and is in its first week there. What the four stages mean
Is SeaStar Medical Holding in an uptrend?
No. SeaStar Medical Holding is in a Stage 4 downtrend. It trades 14.4% below its 200-day average, which is rising.
How far is SeaStar Medical Holding from its 52-week high?
SeaStar Medical Holding closed at $2.85 on Oct 22, 2026, 54.8% below its 52-week high of $6.31. Its 52-week low is $2.21.
How has SeaStar Medical Holding performed over the past year?
As of Oct 22, 2026, SeaStar Medical Holding is down 54.8% over the past year and up 8.4% so far in 2026.
Which sector and industry is SeaStar Medical Holding in?
SeaStar Medical Holding is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.